Izilendustat
Based on 1 Customer Validation
Izilendustat is a potent prolyl hydroxylase inhibitor. Izilendustat competitively inhibits HIFPH2 activity, blocks HIF-1α degradation, stabilizes HIF-1α and HIF-2α proteins, and upregulates downstream target gene expression. Izilendustat can reduce intestinal inflammation and damage, enhance the ability of phagocytes to clear pathogens, and improve ischemia-related pathological phenotypes. Izilendustat can be used for the research of inflammatory bowel disease, ischemic vascular disease and anemia.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.01%
- CAS 番号: 1303512-02-8
- 分子式: C22H28ClN3O4
- 分子量:433.94
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Antibacterial Compound Library
HY-L049
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
生物活性
|
HIF-1α |
HIF-2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
17 μM
Compound: 53
|
Inhibition of PHD2 in HEK293 cells assessed as VEGF release by immunoassay
Inhibition of PHD2 in HEK293 cells assessed as VEGF release by immunoassay
|
[PMID: 23977883] |
Izilendustat (Compound A41) (1.2 μM) inhibits HIFPH2 (EGLN1) activity in enzymatic assays[1].
Izilendustat (Compound A41) (1-50 μM; 7 h) upregulates PGK and VEGF expression in wild-type MEFs but not in HIF-1α knockout MEFs[2].
Izilendustat (10 μM) enhances bacterial clearance in U937 cells infected with S. aureus (Newman or MRSA strain)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Izilendustat (5-10 mg/kg; s.c.; every other day) enhances the antitumor effect of 5-Fluorouracil (HY-90006) in mouse colon 26 carcinoma xenograft models[1].
Izilendustat (Compound A41) (0.5-10 mg/kg; p.o./s.c.; once daily) reduces skin lesion size and bacterial load in S. aureus- and S. pyogenes-infected mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 1303512-02-8
-
性状 Solid
-
分子量 433.94
-
分子式 C22H28ClN3O4
-
Color White to off-white
-
SMILES
O=C(N1CCN(CC(C=CN2CC3=CC=C(Cl)C=C3)=C(O)C2=O)CC1)OC(C)(C)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 25 mg/mL (57.61 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (270 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3045 mL | 11.5223 mL | 23.0447 mL | 57.6117 mL |
| 5 mM | 0.4609 mL | 2.3045 mL | 4.6089 mL | 11.5223 mL | |
| 10 mM | 0.2304 mL | 1.1522 mL | 2.3045 mL | 5.7612 mL | |
| 15 mM | 0.1536 mL | 0.7682 mL | 1.5363 mL | 3.8408 mL | |
| 20 mM | 0.1152 mL | 0.5761 mL | 1.1522 mL | 2.8806 mL | |
| 25 mM | 0.0922 mL | 0.4609 mL | 0.9218 mL | 2.3045 mL | |
| 30 mM | 0.0768 mL | 0.3841 mL | 0.7682 mL | 1.9204 mL | |
| 40 mM | 0.0576 mL | 0.2881 mL | 0.5761 mL | 1.4403 mL | |
| 50 mM | 0.0461 mL | 0.2304 mL | 0.4609 mL | 1.1522 mL |
Izilendustat 関連分類
HY-44809 関連分類
Powered by Bioz